Trial Search Results
Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer
This study will evaluate the safety and tolerability of a personalized live, attenuated, double-deleted Listeria monocytogenes (pLADD) treatment in adults with metastatic colorectal cancer.
Stanford is currently not accepting patients for this trial.
Aduro Biotech, Inc.
Collaborator: Hanlee P. Ji, MD
- Biological: pLADD
- metastatic colorectal cancer (mCRC) that is microsatellite stable (MSS)
- able to provide adequate tumor tissue from at least 1 accessible tumor site
- completed or have developed intolerance to a course of oxaliplatin- or
irinotecan-based frontline therapy at Screening
- on maintenance standard-of-care chemotherapies or on treatment holiday
- Eastern Cooperative Oncology Group (ECOG) 0 or 1
- adequate organ function
- progression of disease at the time of Enrollment
- BRAF V600E mutation
- known allergy to both penicillin and sulfa drugs
- implanted devices that cannot be easily removed
- immunodeficiency, immune compromised state or receiving immunosuppressive therapy
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study